Global /Australia /Healthcare /Drug Manufacturers - General /FRE

Firebrick Pharma Ltd.

FRE

• ASX: FRE • Delayed

0.0550AUD 0%

0.0392 USD

As of 5 June 2026, Firebrick Pharma Ltd. has a market cap of $11.18M USD, ranking #40700 globally and #1297 in Australia. It ranks #3618 in the Healthcare sector, and #1180 in the Drug Manufacturers - General industry.

Global Rank

40700

Country Rank

1297

Sector Rank

3618

Industry Rank

1180

Key Stats

Market Cap

$11.18MUSD

15.66M AUD

Enterprise Value

$10.15MUSD

14.23M AUD

Revenue (TTM)

$293.09KUSD

410.7K AUD

EBITDA (TTM)

-$1.69MUSD

-2.37M AUD

Net Income (TTM)

-$1.75MUSD

-2.45M AUD

PS Ratio

38.1

PB Ratio

8.1

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Peter Molloy open_in_new

Founded

2012

Website

firebrickpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-11%	1.9%	-14%	-14%	3.8%	-21%	-73%	-91%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	FRE Firebrick Pharma Ltd ISIN: AU0000197352 Shares Out.: Shares Outstanding: 285.199M¹ Shares Float: 221.896M² TV: TradingView: ASX: FRE SA: Stock Analysis: ASX: FRE YF: Yahoo Finance: FRE.AX GF: Google Finance: ASX: FRE BA: Barron's: FRE MS: Morningstar: XASX: FRE	0.0550 AUD	TV: TradingView: ASX: FRE SA: Stock Analysis: ASX: FRE YF: Yahoo Finance: FRE.AX GF: Google Finance: ASX: FRE BA: Barron's: FRE MS: Morningstar: XASX: FRE

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Firebrick Pharma Ltd.

Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)

Name	Market Cap (USD) diff.	PE	Country
Sigma Healthcare Ltd. ASX: SIG	$22.82B 31.98B AUD 204K%	52.3	Australia
PYC Therapeutics Ltd. ASX: PYC	$926.22M 1.3B AUD 8K%	-	Australia
Racura Oncology Ltd. ASX: RAC	$346.24M 485.18M AUD 3K%	-	Australia
Clinuvel Pharmaceuticals Ltd. ASX: CUV	$335.4M 469.99M AUD 3K%	14.5	Australia
Starpharma Holdings Ltd. ASX: SPL	$216.39M 303.23M AUD 2K%	-	Australia
Mayne Pharma Group Ltd. ASX: MYX	$166.4M 233.18M AUD 1K%	-	Australia

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 7M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 5M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 3M%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 3M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 3M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 2M%	20.5	Switzerland

chevron_leftBack